CytomX Therapeutics, Inc. Unrecognized Tax Benefits that Would Impact Effective Tax Rate
CytomX Therapeutics, Inc. (CTMX) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $2.30 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-03-16
- 2025-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $2.30M.
- 2025-09-30: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $5.00M.
- 2025-06-30: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $5.10M.
- 2025-03-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $5.10M.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate as first filed |
|---|---|---|
| 2025-12-31 | $2.30M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $5.00M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $5.10M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $5.10M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $2.30M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $4.10M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $4.00M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $3.90M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $2.30M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $2.80M 10-Q · filed 2023-11-07 | |
| 2022-12-31 | $2.30M 10-K · filed 2024-03-11 | $0.00 10-K · filed 2023-03-27 |
| 2021-12-31 | $0.00 10-K/A · filed 2023-03-27 | |
| 2020-12-31 | $0.00 10-K/A · filed 2023-03-27 | |
| 2019-12-31 | $900.00K 10-K/A · filed 2023-03-27 | |
| 2018-12-31 | $1.00M 10-K · filed 2021-02-24 | |
| 2017-12-31 | $0.00 10-K · filed 2019-02-27 | |
| 2016-12-31 | $0.00 10-K · filed 2017-03-02 | |
| 2015-12-31 | $0.00 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |